ATHA - Athira Pharma Inc Stock Price, Fair Value and News

$4.02-0.18 (-4.29%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ATHA Price Action

Last 7 days

-11.1%

Last 30 days

-3.8%

Last 90 days

3.9%

Trailing 12 Months

-36.2%

ATHA RSI Chart

ATHA Valuation

Market Cap

15.9M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

100.73

Price/Free Cashflow

-0.3

ATHA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ATHA Fundamentals

ATHA Revenue

Revenue (TTM)

157.0K

ATHA Earnings

Earnings (TTM)

-37.7M

Earnings Growth (Yr)

77%

Earnings Growth (Qtr)

5.1%

ATHA Profitability

Return on Equity

-140.9%

Return on Assets

-125.67%

Free Cashflow Yield

-330.16%

ATHA Investor Care

Shares Dilution (1Y)

1.99%

Diluted EPS (TTM)

-9.63

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.9M	2.7M	1.4M	157.0K
2022	9.2M	7.9M	6.5M	5.2M
2021	3.2M	5.1M	7.0M	8.8M
2020	1.0M	0	0	1.3M
2019	0	0	0	754.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Athira Pharma Inc

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

CEO	Dr. Mark J. Litton M.B.A., MBA, Ph.D.
WEBSITE	athira.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	63

Athira Pharma Inc Frequently Asked Questions

What is the ticker symbol for Athira Pharma Inc? What does ATHA stand for in stocks?

ATHA is the stock ticker symbol of Athira Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Athira Pharma Inc (ATHA)?

As of Wed Dec 03 2025, market cap of Athira Pharma Inc is 15.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATHA stock?

You can check ATHA's fair value in chart for subscribers.

Is Athira Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether ATHA is over valued or under valued. Whether Athira Pharma Inc is cheap or expensive depends on the assumptions which impact Athira Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATHA.

What is Athira Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ATHA's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 100.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATHA PE ratio will change depending on the future growth rate expectations of investors.